The European Medicines Agency granted an orphan drug designation to ImMucin for the treatment of multiple myeloma. ImMucin targets the less studied signal peptide domain of the MUC1 tumor antigen.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe